Business Context and Reporting Period
This Form 8-K was filed by Ginkgo Bioworks Holdings, Inc. on November 12, 2024, reporting events occurring on November 6 and November 7, 2024. The filing primarily addresses changes to the Board of Directors and references the issuance of a press release regarding financial results for the third quarter ended September 30, 2024.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity for the third quarter of 2024. These figures are contained in the referenced press release (Exhibit 99.1) but are not detailed within the body of this 8-K document.
Regarding specific contractual revenue, the Company expects to receive approximately $330,000 from its commercial partner, Octant Bio, during the 2024 fiscal year under an existing contract for Reconfigurable Automation Carts and support services.
Material Changes
- Board Appointment: Dr. Sri Kosuri was appointed as a Class B director on November 6, 2024. His term expires at the 2025 annual meeting of shareholders.
- Board Resignation: Dr. Arie Belldegrun resigned from the Board on November 7, 2024, ending his service which began in September 2021.
- Compensation Arrangements: Dr. Kosuri received an option to purchase 91,151 shares of Class A common stock and 24,067 restricted stock units upon appointment. He is eligible for an annual retainer of $50,000 plus future equity awards.
Outlook, Risks, and Management Commentary
The filing highlights a potential conflict of interest or related party transaction involving Dr. Kosuri. He is the CEO of Octant Bio, a commercial partner of Ginkgo Bioworks. Additionally, Ginkgo's CEO, Jason Kelly, serves on Octant's board of directors. The Company disclosed the specific revenue expectation from this partnership to ensure transparency.
Dr. Kosuri brings significant experience in synthetic biology and gene synthesis, having previously worked at the Wyss Institute at Harvard University and helped build Gen9, which was acquired by Ginkgo in 2017.
Investor Verification Checklist
- Review the full Q3 2024 press release (Exhibit 99.1) for actual revenue, net loss, and cash burn figures, as they are not listed in this 8-K.
- Verify the independence status of the Board following the appointment of Dr. Kosuri, given his role as CEO of a commercial partner (Octant Bio).
- Confirm the impact of Dr. Belldegrun's resignation on the composition of the Compensation Committee.
- Monitor the execution of the contract with Octant Bio to ensure the projected $330,000 revenue is realized.